Comparative Pharmacology
Head-to-head clinical analysis: PROMETH PLAIN versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETH PLAIN versus SEMPREX D.
PROMETH PLAIN vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination